VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to participate in the LifeSci Partners 12th Annual Corporate Access Event during the J.P. Morgan Healthcare Conference in San Francisco, CA. Scheduled for January 10-11, 2023, the company will conduct one-on-one meetings at the Beacon Grand Hotel.
VYNE focuses on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary bromodomain & extra-terminal (BET) domain platform, which includes lead programs VYN201 and VYN202.
Positive
- None.
Negative
- None.
News Market Reaction – VYNE
In the trading session that priced this news, VYNE declined 14.94%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings.
| One-on-One Meeting Details | |
| Meeting Dates: | January 10-11, 2023 |
| Location: | Beacon Grand Hotel |
| Format: | 1-on-1, in-person meetings |
*For more information or to request a meeting please register here
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
